First Patient is Enrolled in Lumos Study. Objective: to Evaluate Safety and Potential Efficacy of rhNGF in the Treatment of Retinitis Pigmentosa

News provided by

Dompe

03 Apr, 2014, 11:31 GMT

MILAN, April 3, 2014 /PRNewswire/ --



  • Retinitis pigmentosa is a rare disease of genetic origin that can lead to gradual loss of vision. It affects more than one million people worldwide[1], 12/17,000 in Italy alone, and there is currently no curative therapy available. 
  • The study, in Phase Ib/II, will involve 5 centres and 50 patients in Italy. 
  • Recombinant human Nerve Growth Factor (rhNGF), developed and manufactured by the Dompé Group and based on the research ofNobel Prize winner Rita Levi Montalcini, recently received orphan drug designation from the European Medicines Agency (EMA) and the United States FDA regulatory agencies for the treatment of Retinitis pigmentosa. 

Research for a new treatment for retinitis pigmentosa (RP), a genetic disease affecting an average of one person every 3,500-5,000[2] is currently being carried out exclusively in Italy.

This line of investigation originates from the research of Rita Levi Montalcini, winner of the 1986 Nobel Prize for Medicine, into the identification of nerve growth factors. The work relating to the studies of this eminent scientist is being continued by Dompé,  Italian biopharmaceutical company engaged in the research of new therapeutic solutions for the treatment of rare and orphan diseases, which is developing rhNGF (recombinant human Nerve Growth Factor) for ophthalmic use.

The molecule - currently in clinical development for the treatment of neurotrophic keratitis (a rare disease of the cornea) in the Reparo study, involving 158 patients in 39 centres in nine European countries - is now being evaluated for its safety profile and to obtain preliminary efficacy data, as part of the Lumos study, involving five centres of excellence in Italy. The first patient was enrolled at the CareggiUniversityHospital in Florence.

Lumos is a Phase Ib/II, multicentre, randomised, double-masked, placebo-controlled study that aims to assess the safety and potential efficacy of rhNGF eye drops in two doses (60 and 180 µg/ml), compared to a placebo. The research will involve 50 patients, who will be enrolled at five centres in Florence, Milan, Rome (two centres) and Naples, internationally recognised for their expertise in this therapeutic area. Patients with typical retinitis pigmentosa will be divided into three groups. The first will be given eye drops at the lower dose, the second an increased dose and the third placebo eye drops. The monitoring schedule for each patient is 24 weeks.

"Retinitis pigmentosa is a great challenge for ophthalmology, because it is a disease which still has no cure," explains Francesca Simonelli, Director of Clinical Ophthalmology at the Second University of Naples. "In patients who suffer from this chronic disease, the photoreceptors (retinal cells called cones and rods whose task it is to capture visual signals and send them the brain) are damaged and undergo progressive degeneration, there being no way of stopping the pathological process.We are, therefore, very interested in potential treatments such as that offered by rhNGF, which could lead to new perspectives in the treatment of retinitis pigmentosa."

rhNGF has been developed by Dompé and is produced at their L'Aquila facilities using recombinant DNA technology, that is, through the transfer to bacteria of human genetic material. Bacteria become the drug "factory," producing material equivalent to the growth factor produced by the human body.

"We are proud to announce the start of the Lumos study and the news of the first enrolment," explains Eugenio Aringhieri, CEO of the Dompé Group. "This is further evidence of our commitment to protecting the patient, in researching therapeutic solutions in areas of high demand for healthcare, such as the treatment of rare and often orphan diseases. Commitment to research and development is at the heart of our Group objectives and our mission, which is directly related to the unsatisfied therapeutic needs of patients throughout the world. We will continue to focus on our ability to generate innovation, making use of the fundamental contributions of a network of 70 international centres of excellence, with the aim of making significant advances in respect of currently available therapeutic solutions, in areas such as Ophthalmology, Organ Transplant and Oncology."

For more information about rhNGF and Retinitis Pigmentosa: http://www.dompe.com/Ophthalmology/

For more information about Dompé: http://www.dompe.com

This press release may contain forward looking statements. Dompé firmly believes the expectations reflected in forward looking statements are reasonable and built on sound assumptions. However, by their very nature, forward looking statements are subject to uncertainties including those inherent in R&D and those associated with decisions made by regulatory authorities. Hence, forward looking statements are not a guarantee of future results which may be different.

References: 

  1. Source: Anasagasti A, Irigoyen C, Barandika O, et. al. Current mutation discovery approaches in retinitis pigmentosa, Vision Res. 2012; 75: 117-129.
  2. Idem.